Want to see PULM full AI Analyst Report?
PULM Stock Chart & Stats
$2.35
-$0.25(-3.99%)
At close: 4:00 PM EST
$2.35
-$0.25(-3.99%)
Day’s Range― - ―
52-Week Range$1.16 - $6.83
Previous CloseN/A
Volume31.27K
Average Volume (3M)7.19K
Market Cap
$6.87M
Enterprise Value$2.15M
Total Cash (Recent Filing)$3.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding3,652,285
10 Day Avg. Volume4,700
30 Day Avg. Volume7,194
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.14
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-41.43
Enterprise Value/Ebitda-0.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$16.45M
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtPulmatrix reports zero total debt across recent periods, which meaningfully reduces solvency risk for a clinical-stage biotech. Low leverage preserves strategic optionality to fund trials via equity or partnerships, avoids interest burden, and improves resilience to trial delays or market stress.
Narrowing LossesReported net losses have declined materially over several years, indicating improved cost control or program prioritization. A sustained reduction in operating losses lengthens runway, reduces near-term financing needs, and increases the likelihood management can reach clinical or partnering milestones without emergency dilutive raises.
Strategic Financing And Merger SupportThe $1M Series B preferred placement and planned merger with Eos SENOLYTIX provide immediate working capital and a strategic partner. This structural financing and transaction can extend the runway, supply development resources, and create a new corporate profile that may enhance commercialization prospects if the deal closes.
Bears Say
Inconsistent / No RevenuePulmatrix lacks sustained commercial revenue, with TTM sales at zero versus a prior $7.8M. Reliance on sporadic or nonrecurring revenue means the business model is funding-dependent; without predictable revenue streams, the company must continually seek financing or partnerships to sustain R&D and operations over the medium term.
Persistent Negative Cash FlowOperating and free cash flows remain materially negative, reflecting ongoing cash burn despite improvement. Continued negative cash generation necessitates recurring capital raises, increasing dilution risk and constraining the ability to finance larger trials or commercial activities without external support or strategic deals.
Eroded Equity And Shrinking AssetsThe equity base and total assets have contracted sharply over several years, reflecting cumulative losses and asset drawdown. A materially weakened balance sheet reduces financial flexibility, limits collateral for financing, and heightens vulnerability to clinical setbacks or deal failures that could require rapid capital infusions.
Pulmatrix News
PULM FAQ
What was Pulmatrix’s price range in the past 12 months?
Pulmatrix lowest stock price was $1.16 and its highest was $6.83 in the past 12 months.
What is Pulmatrix’s market cap?
Pulmatrix’s market cap is $6.87M.
When is Pulmatrix’s upcoming earnings report date?
Pulmatrix’s upcoming earnings report date is Aug 12, 2026 which is in 33 days.
How were Pulmatrix’s earnings last quarter?
Pulmatrix released its earnings results on May 15, 2026. The company reported -$0.321 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.321.
Is Pulmatrix overvalued?
According to Wall Street analysts Pulmatrix’s price is currently Overvalued.
Does Pulmatrix pay dividends?
Pulmatrix does not currently pay dividends.
What is Pulmatrix’s EPS estimate?
Pulmatrix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pulmatrix have?
Pulmatrix has 3,652,285 shares outstanding.
What happened to Pulmatrix’s price movement after its last earnings report?
Pulmatrix reported an EPS of -$0.321 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.575%.
Which hedge fund is a major shareholder of Pulmatrix?
Currently, no hedge funds are holding shares in PULM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pulmatrix
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
1.84% Mutual Funds
0.56% Other Institutional Investors
96.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---